BeOne Medicines (ONC) Capital Expenditures (2015 - 2026)

BeOne Medicines (ONC) has reported Capital Expenditures for 12 consecutive years, with $43.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures fell 27.93% year-over-year to $43.2 million; the TTM figure through Mar 2026 stood at $40.5 million (up 254.35% YoY), while the FY2025 annual figure was $57.3 million, down 18.53% from the prior year.
• Capital Expenditures advanced to $43.2 million in Q1 2026 per ONC's latest filing, from -$91.0 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $183.0 million in Q2 2023 and bottomed at -$139.4 million in Q3 2023.
• Historically, Capital Expenditures has averaged $34.6 million across 5 years, with a median of $43.2 million in 2026.
• Annual changes were most pronounced in 2023 — Capital Expenditures jumped 1251.36% — and 2025, when it tumbled 1719.59%.
• BeOne Medicines' Capital Expenditures stood at $121.4 million in 2022, then sank by 113.03% to -$15.8 million in 2023, then jumped by 68.35% to -$5.0 million in 2024, then sank by 1719.59% to -$91.0 million in 2025, then surged by 147.51% to $43.2 million in 2026.
• Business Quant data shows ONC's Capital Expenditures at $43.2 million in Q1 2026, -$91.0 million in Q4 2025, and $48.1 million in Q3 2025.